DJIA 17,814.94 -2.96 -0.02%
NASDAQ 4,758.25 3.36 0.07%
S&P 500 2,067.03 -2.38 -0.12%
market minute promo

Gilead Sciences (NASDAQ: GILD)

101.11 0.51 (0.51%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

GILD $101.11 0.51%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $100.95
Previous Close $100.60
Daily Range $98.37 - $101.38
52-Week Range $63.50 - $116.83
Market Cap $152.5B
P/E Ratio 17.84
Dividend (Yield) $0.00 (0.0%)
Volume 20,571,077
Average Daily Volume 16,760,555
Current FY EPS $7.93

Sector

Healthcare

Industry

Drugs

Gilead Sciences (GILD) Description

Gilead Sciences created and sells the world’s top-selling HIV medications, Truvada and Atripla, and commands about 75% of the U.S. treatment market and more than 50% worldwide. Website: http://www.gilead.com/

News & Commentary

3 Simple Reasons Doctors May Stick With Gilead Sciences Instead of AbbVie

Gilead Sciences hepatitis C drug Harvoni offers three important advantages over AbbVie's competing hepatitis C drug cocktail.

Dow Chemical, NXP Semi, Gilead Sciences Set for Gains, Lucia Capital CEO Says

For Gilead, Are Products More Important Than Price?

Why You Shouldn't Bet Against Gilead Sciences (GILD) Stock - Tale of the Tape

3 Stocks Underperforming Today In The Drugs Industry

Despite Recent Hiccup, Gilead Is Still A Blue Chip Gem

3 Biotech Growth Stocks You Can Buy Right Now

These three biotech growth stocks may have already delivered impressive gains to investors, but there could still be plenty of room left for them to head even higher.

AbbVie Takes Aim at Gilead Sciences

AbbVie has won support from a key advisory committee for its new hepatitis C drug cocktail.

AbbVie's HCV Cocktail Treatment Closer to EU Approval - Analyst Blog

Can Partnering To Fight Hepatitis C Pay At Enanta?

See More GILD News...

GILD's Top Competitors

GILD $101.11 (0.51%)
Current stock: GILD
AMGN $162.24 (-1.18%)
Current stock: AMGN
CELG $111.07 (0.08%)
Current stock: CELG
$0.00 (0.00%)
Current stock: